Advertisement
Advertisement

PLUR

PLUR logo

Pluri Inc. Common Stock

3.48
USD
Sponsored
+0.15
+4.34%
May 08, 15:08 UTC -4
Closed
exchange

After-Market

3.47

-0.01
-0.43%

PLUR Earnings Reports

Positive Surprise Ratio

PLUR beat 19 of 30 last estimates.

63%

Next Report

Tomorrow
Date of Next Report
May 11, 2026
Estimate for Q3 26 (Revenue/ EPS)
$668.10K
/
-$0.67
Implied change from Q2 26 (Revenue/ EPS)
+237.42%
/
-5.63%
Implied change from Q3 25 (Revenue/ EPS)
--
/
--

Pluri Inc. Common Stock earnings per share and revenue

On Feb 12, 2026, PLUR reported earnings of -0.71 USD per share (EPS) for Q2 26, missing the estimate of -0.66 USD, resulting in a -7.09% surprise. Revenue reached 198.00 thousand, compared to an expected 650.76 thousand, with a -69.57% difference. The market reacted with a +0.28% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 3 analysts forecast an EPS of -0.67 USD, with revenue projected to reach 668.10 thousand USD, implying an decrease of -5.63% EPS, and increase of 237.42% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Werewolf Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.29
Actual
-$0.28
Surprise
+3.68%
logo
argenx SE - ADR
Report Date
May 07, 2026 For Q1 26
Estimate
$5.47
Actual
$5.52
Surprise
+0.86%
logo
Arrowhead Research Corporation
Report Date
May 07, 2026 For Q2 26
Estimate
-$1.16
Actual
-$0.93
Surprise
+20.32%
logo
ImmunityBio, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-26.05%
logo
Stoke Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.84
Actual
-$0.79
Surprise
+6.34%
logo
ANI Pharmaceuticals, Inc.
Report Date
May 08, 2026 For Q1 26
Estimate
$1.33
Actual
$2.04
Surprise
+54.04%
logo
Harmony Biosciences Holdings, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$0.72
Actual
$0.55
Surprise
-24.16%
logo
CytomX Therapeutics, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.10
Surprise
+18.83%
logo
Tectonic Therapeutic, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.20
Actual
-$1.34
Surprise
-11.07%
logo
ALX Oncology Holdings Inc. Common Stock
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.22
Actual
-$0.17
Surprise
+24.24%
FAQ
For Q2 2026, Pluri Inc. Common Stock reported EPS of -$0.71, missing estimates by -7.09%, and revenue of $198.00K, -69.57% below expectations.
The stock price moved up 0.28%, changed from $3.55 before the earnings release to $3.56 the day after.
The next earning report is scheduled for May 11, 2026.
Based on 3 analysts, Pluri Inc. Common Stock is expected to report EPS of -$0.67 and revenue of $668.10K for Q3 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement